Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 612.88 Delayed Data As of Aug 12 |  +14.02 / +2.34%Today’s Change | 271.37 Today|||52-Week Range 664.64 | +63.23% Year-to-Date |
Latest REGN News | Press Releases
| FDA accepts Regeneron application for evinacumab for inherited cholesterol disorder Aug 12 / Seeking Alpha - Paid Partner Content | Regeneron lands BARDA contract for Ebola cocktail Jul 29 / Seeking Alpha - Paid Partner Content |
| Merck to Begin Pivotal COVID-19 Antiviral Studies in September Jul 31 / MotleyFool.com - Paid Partner Content | Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players Jul 28 / Seeking Alpha - Paid Partner Content |
| Regeneron teams up with BioNTech in melanoma Jul 31 / Seeking Alpha - Paid Partner Content | Biotech Bonanza - Second Half Outlook Jul 28 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 598.86 |
| Today’s open | 599.89 |
| Day’s range | 599.89 - 617.00 |
| Volume | 24,449 |
| Average volume (3 months) | 1,182,350 |
| Market cap | $66.0B |
Data as of 6:00pm ET, 08/12/2020
Growth & Valuation
| Earnings growth (last year) | -14.46% |
| Earnings growth (this year) | +22.85% |
| Earnings growth (next 5 years) | +12.50% |
| Revenue growth (last year) | +17.18% |
| P/E ratio | 23.8 |
| Price/Sales | 5.47 |
| Price/Book | 6.17 |
Competitors
Data as of 4:05pm ET, 08/12/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | $7.29 |
| Annual revenue (last year) | $7.9B |
| Annual profit (last year) | $2.1B |
| Net profit margin | 26.91% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
